STAT+: CRISPR edits fail to cure HIV patients in early test
BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in…
Category: HIV
Opinion: STAT+: A California court is setting a dangerous precedent over drug development (or lack thereof) liability
The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate…
‘Last roll of the dice’ for a near-term HIV vaccine fails
A study billed as the last chance to develop an HIV vaccine this decade has…
Listen: Is the Nobel committee evolving? Plus, preventing public health’s wiliest virus
Will we ever get an HIV vaccine? And is the oft-criticized institution that awards the…
Here’s what’s moving the needle in biotech stock, in the final quarter of a dismal year
Want to stay on top of the science and politics driving biotech today? Sign up…
Can the world still invent an HIV vaccine? Progress in one area creates new problem
Louis Picker is nervous. Last month, the first volunteer was injected with an HIV vaccine…
STAT+: Gilead foresees more growth in its HIV drugs
Gilead Sciences is famous — or perhaps, notorious — for its cure for hepatitis C….
STAT+: A battle between Gilead and the U.S. government over patents on HIV prevention pills goes to trial
After years of sparring, the federal government and Gilead Sciences will square off in a…
STAT+: Gilead wins a key battle with the CDC over patents for its Truvada HIV pill
Gilead Sciences won a key round in its battle with the U.S. government over allegations…
Judge invalidates parts of the ACA that mandate health coverage of many preventive services and drugs
A federal judge in Texas has ruled that parts of the Affordable Care Act mandating…
STAT+: ViiV will make it easier for generic companies to copy its HIV prevention shot, but it’s not clear when
In response to criticism, ViiV Healthcare has agreed to license its long-acting injectable HIV prevention…